Yes very good D T !!
Printable View
Thats when the rich get richer. When you have money you have less fear of loosing money and in turn can snap up shares when they bottom like this. Then sit back, wait and make serious wealth. It's harder for the small or mid level investor to stomach seeing an SP drop, so they sell out of fear, then inevitably miss the rally back up. Which happens just as quick as a fall on the next turn around of positive news again. Those that follow Buffet style mentality make the big gains. Maxed out on funds - wish had more at times like this to be able to capitalise.
CMS reimbursement represents 40% of PEB's total market, however CMS will only reimburse if the tests are considered medically necessary. Of the tests reimbursed by CMS, how many were considered to be medically necessary?
It appears to me that if all of them or at least 80% were considered medically necessary, Novitas may have a hard job justifying relegating detect and monitor to group 6.
I would not want to be caught short if the final decision is to remove these tests from group 6.
Happy to hold
Another question has sprung to mind with a modicum of sleep.
Please remain seated.
Where is the Triage test used for delineating and stratifying those presenting with blood in the urine?
It appears that this hasn't even got to first base with CMS compensation as yet.
Still coming, along with Resolve I suppose.
Could add a bit of vinegar to the whole situation if Novitas get told to pull their heads in and leave things alone.
Still in way oversold RSI territory. Markets have a tendency to over react as they did, a 48% drop was obvious knee jerk premature reaction, folk seem to be realising this as seen in SP yesterday and today. Hence for those who bought in and are still buying in at todays levels are seeing sizeable returns. Often the case buy the fear sell the Hype.
Also it raises the question why would Novitas want to take this approach at all at this current stage!???
As to the question on why Novitas would take this approach, it highlights to me that the success of CXBladder is not only determined by the efficacy of the product, but also by various lobby/vested interest groups and the many other complicated dynamics of bringing a new product to market - some of which PEB can influence!